Clover (ASX:CLV) said that the recent recall actions in the infant formula market relate exclusively to contamination detected in a batch of arachidonic acid oil supplied by an unrelated third-party manufacturer and that it does not source, supply, or have any commercial or technical association with the supplier involved, according to a Thursday Australian bourse filing.

It added that all of its products are safe, fully compliant with all applicable regulations, and are unaffected by the issues currently impacting certain infant formula manufacturers, after undertaking routine controls, supported by targeted additional testing.

The firm said it was assisting customers in evaluating alternative formulation pathways, as well as providing expert guidance on supply continuity planning.